1. Market Research
  2. > Healthcare
  3. > Medical Device
  4. > In Vitro Diagnostics Market Trends
  5. > Cervical Cancer Test Market & Patients - Pap Smear, HPV DNA, VIA – Test & Patients – Worldwide

Cervical cancer is one of the deadliest cancers among woman all over the world. However in the past few decades, mortality from cervical cancer has significantly decreased in developed countries due to widely use of Pap smear test. HPV DNA and VIA test are other popular tests used across world. VIA test is most adoptable test in developing countries as it is cheaper in comparison to Pap smear test and HPV DNA test.

Cervical cancer test market is dominated by United States in 2013. Germany and United Kingdom are other top two leaders in this market place. In Asian region, China and India are top two countries having largest cervical cancer test population. Few countries have also shown a decline in cervical cancer test market. However VIA test market accounts for largest share in cervical cancer test market in the case of developing countries like India and China.

A high prevalence of HPV-infected patients across the globe, rising incidences of teenage sexual cases, a rising number of organized cervical cancer programs initiated by governments and NGOs and introduction of low cost VIA test are some of the major growth drivers for the cervical cancer test market. However, lack of insufficient healthcare infrastructure and lack of cervical cancer screening awareness are the major hinder for cervical testing market.

Renub Research report titled "Cervical Cancer Test Market & Patients - Pap Smear, HPV DNA, VIA – Test & Patients – Worldwide” provides a comprehensive analysis of the current state of this market and likely future evolution over the next 5 years. This 232 page report with 240 Figures and 14 Table provides a complete analysis of top 20 Countries Cervical Cancer Test Market & Population.

All the 20 countries in the report have been studied from 3 viewpoints.

1. Cervical cancer Test Population (2007-2020)
• Pap smear test population (2007-2020)
• HPV DNA test population (2007-2020)
• VIA test Population (2007-2020)

2. Cervical Cancer Mortality Population (2001-2011)

3. Cervical Cancer Test Market (2007-2020)
• Pap smear test market (2007-2020)
• HPV DNA test market (2007-2020)
• VIA test market (2007-2020)

All the 20 Countries studied in the report are as follows

1. United Kingdom
2. France
3. Germany
4. Italy
5. Spain
6. Sweden
7. Switzerland
8. Norway
9. Netherlands
10. United States
11. Canada
12. Japan
13. Korea
14. Singapore
15. Malaysia
16. Australia
17. India
18. China
19. Thailand
20. Indonesia

Data Sources

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts. Primary sources include industry surveys and telephone interviews with industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Table Of Contents

Cervical Cancer Test Market and Patients - Pap Smear, HPV DNA, VIA - Test and Patients - Worldwide
1. Executive Summary

2. Worldwide Cervical Cancer Test (Screening) Population and Forecast

3. Worldwide Cervical Cancer Test (Screening) Market and Forecast
3.1 Worldwide Cervical Cancer Pap Smear Test (Screening) Market and Forecast
3.2 Worldwide Cervical Cancer HPV DNA Test (Screening) Market and Forecast
3.3 Worldwide - Cervical Cancer Visual Inspection with Acetic Acid (VIA) Test (Screening) Market and Forecast

4. Worldwide Cervical Cancer Test (Screening) Population Share, Market Share and Forecast
4.1 Worldwide Cervical Cancer Test (Screening) Population Share and Forecast
4.2 Worldwide Cervical Cancer Test (Screening) Market Share and Forecast
4.3 Worldwide Cervical Cancer Pap Smear Test (Screening) Market Share and Forecast
4.4 Worldwide Cervical Cancer HPV DNA Test (Screening) Market Share and Forecast
4.5 Worldwide Cervical Cancer VIA Test (Screening) Market Share and Forecast

5. United Kingdom - Cervical Cancer Test Analysis

5.1 United Kingdom Cervical Cancer Test (Screening) Population
5.1.1 United Kingdom Cervical Cancer Pap Smear Test Population and Forecast
5.1.2 United Kingdom Cervical Cancer HPV DNA Test Population and Forecast

5.2 United Kingdom Cervical Cancer Mortality

5.3 United Kingdom Cervical Cancer Test (Screening) Analysis
5.3.1 United Kingdom Cervical Cancer Test Market and Forecast
5.3.2 United Kingdom Pap Smear Test Market and Forecast
5.3.3 United Kingdom HPV DNA Test Market and Forecast

6. France - Cervical Cancer Test Analysis
6.1 France Cervical Cancer Test (Screening) Population
6.1.1 France Cervical Cancer Pap Smear Test Population and Forecast
6.1.2 France Cervical Cancer HPV DNA Test Population and Forecast

6.2 France Cervical Cancer Mortality

6.3 France Cervical Cancer Test (Screening) Analysis
6.3.1 France Cervical Cancer Test Market and Forecast
6.3.2 France Pap Smear Test Market and Forecast
6.3.3 France HPV DNA Test Market and Forecast

7. Germany - Cervical Cancer Test Analysis
7.1 Germany Cervical Cancer Test (Screening) Population
7.1.1 Germany Cervical Cancer Pap Smear Test Population and Forecast
7.1.2 Germany Cervical Cancer HPV DNA Test Population and Forecast

7.2 Germany Cervical Cancer Mortality

7.3 Germany Cervical Cancer Test (Screening) Market
7.3.1 Germany Cervical Cancer Test Market and Forecast
7.3.2 Germany Pap Smear Test Market and Forecast
7.3.3 Germany HPV DNA Test Market and Forecast

8. Italy - Cervical Cancer Test Analysis
8.1 Italy Cervical Cancer Test (Screening) Population
8.1.1 Italy Cervical Cancer Pap Smear Test Population and Forecast
8.1.2 Italy Cervical Cancer HPV DNA Test Population and Forecast

8.2 Italy Cervical Cancer Mortality

8.3 Italy Cervical Cancer Test (Screening) Market
8.3.1 Italy Cervical Cancer Test Market and Forecast
8.3.2 Italy Pap Smear Test Market and Forecast
8.3.3 Italy HPV DNA Test Market and Forecast

9. Spain - Cervical Cancer Test Analysis
9.1 Spain Cervical Cancer Test (Screening) Population
9.1.1 Spain Cervical Cancer Pap Smear Test Population and Forecast
9.1.2 Spain Cervical Cancer HPV DNA Test Population and Forecast

9.2 Spain Cervical Cancer Mortality

9.3 Spain Cervical Cancer Test (Screening) Market
9.3.1 Spain Cervical Cancer Test Market and Forecast
9.3.2 Spain Pap Smear Test Market and Forecast
9.3.3 Spain HPV DNA Test Market and Forecast

10. Sweden - Cervical Cancer Test Analysis
10.1 Sweden Cervical Cancer Test (Screening) Population
10.1.1 Sweden Cervical Cancer Pap Smear Test Population and Forecast
10.1.2 Sweden Cervical Cancer HPV DNA Test Population and Forecast

10.2 Sweden Cervical Cancer Mortality

10.3 Sweden Cervical Cancer Test (Screening) Market
10.3.1 Sweden Cervical Cancer Test Market and Forecast
10.3.2 Sweden Pap Smear Test Market and Forecast
10.3.3 Sweden HPV DNA Test Market and Forecast

11. Switzerland - Cervical Cancer Test Analysis
11.1 Switzerland Cervical Cancer Test (Screening) Population
11.1.1 Switzerland Cervical Cancer Pap Smear Test Population and Forecast
11.1.2 Switzerland Cervical Cancer HPV DNA Test Population and Forecast

11.2 Switzerland Cervical Cancer Mortality

11.3 Switzerland Cervical Cancer Test (Screening) Market
11.3.1 Switzerland Cervical Cancer Test Market and Forecast
11.3.2 Switzerland Pap smear Test Market and Forecast
11.3.3 Switzerland HPV DNA Test Market and Forecast

12. Norway - Cervical Cancer Test Analysis
12.1 Norway Cervical Cancer Test (Screening) Population
12.1.1 Norway Cervical Cancer Pap Smear Test Population and Forecast
12.1.2 Norway Cervical Cancer HPV DNA Test Population and Forecast

12.2 Norway Cervical Cancer Mortality

12.3 Norway Cervical Cancer Test (Screening) Market
12.3.1 Norway Cervical Cancer Test Market and Forecast
12.3.2 Norway Pap Smear Test Market and Forecast
12.3.3 Norway HPV DNA Test Market and Forecast

13. Netherlands - Cervical Cancer Test Analysis
13.1 Netherlands Cervical Cancer Test (Screening) Population
13.1.1 Netherlands Cervical Cancer Pap Smear Test Population and Forecast
13.1.2 Netherlands Cervical Cancer HPV DNA Test Population and Forecast

13.2 Netherlands Cervical Cancer Mortality

13.3 Netherlands Cervical Cancer Test (Screening) Market
13.3.1 Netherlands Cervical Cancer Test Market and Forecast
13.3.2 Netherlands Pap Smear Test Market and Forecast
13.3.3 Netherlands HPV DNA Test Market and Forecast

14. United States - Cervical Cancer Test Analysis
14.1 United States Cervical Cancer Test (Screening) Population
14.1.1 United States Cervical Cancer Pap Smear Test Population and Forecast
14.1.2 United States Cervical Cancer HPV DNA Test Population and Forecast

14.2 United States Cervical Cancer Mortality

14.3 United States Cervical Cancer Test (Screening) Market
14.3.1 United States Cervical Cancer Test Market and Forecast
14.3.2 United States Pap smear Test Market and Forecast
14.3.3 United States HPV DNA Test Market and Forecast

15. Canada - Cervical Cancer Test Analysis
15.1 Canada Cervical Cancer Test (Screening) Population
15.1.1 Canada Cervical Cancer Pap Smear Test Population and Forecast
15.1.2 Canada Cervical Cancer HPV DNA Test Population and Forecast

15.2 Canada Cervical Cancer Mortality

15.3 Canada Cervical Cancer Test (Screening) Market
15.3.1 Canada Cervical Cancer Test Market and Forecast
15.3.2 Canada Pap Smear Test Market and Forecast
15.3.3 Canada HPV DNA Test Market and Forecast

16. Japan - Cervical Cancer Test Analysis
16.1 Japan Cervical Cancer Test (Screening) Population
16.1.1 Japan Cervical Cancer Pap Smear Test Population and Forecast
16.1.2 Japan Cervical Cancer HPV DNA Test Population and Forecast

16.2 Japan Cervical Cancer Mortality

16.3 Japan Cervical Cancer Test (Screening) Market
16.3.1 Japan Cervical Cancer Test Market and Forecast
16.3.2 Japan Pap Smear Test Market and Forecast
16.3.3 Japan HPV DNA Test Market and Forecast

17. South Korea - Cervical Cancer Tests Analysis
17.1 South Korea - Cervical Cancer Test (Screening) Population
17.1.1 South Korea - Cervical Cancer Pap Smear Test Population and Forecast
17.1.2 Korea Cervical Cancer HPV DNA Test Population and Forecast

17.2 Korea Cervical Cancer Mortality

17.3 Korea Cervical Cancer Test (Screening) Market
17.3.1 Korea Cervical Cancer Test Market and Forecast
17.3.2 Korea Pap Smear Test Market and Forecast
17.3.3 Korea HPV DNA Test Market and Forecast

18. Singapore - Cervical Cancer Tests Analysis
18.1 Singapore - Cervical Cancer Test (Screening) Population
18.1.1 Singapore - Cervical Cancer Pap Smear Test Population and Forecast
18.1.2 Singapore Cervical Cancer HPV DNA Test Population and Forecast

18.2 Singapore Cervical Cancer Test (Screening) Market
18.2.1 Singapore Cervical Cancer Test Market and Forecast
18.2.2 Singapore Pap Smear Test Market and Forecast
18.2.3 Singapore HPV DNA Test Market and Forecast

19. Malaysia - Cervical Cancer Test Analysis
19.1 Malaysia - Cervical Cancer Test (Screening) Population
19.1.1 Malaysia Cervical Cancer Pap Smear Test Population and Forecast
19.1.2 Malaysia Cervical Cancer HPV DNA Test Population and Forecast

19.2 Malaysia Cervical Cancer Test (Screening) Market
19.2.1 Malaysia Cervical Cancer Test Market and Forecast
19.2.2 Malaysia Pap Smear Test Market and Forecast
19.2.3 Malaysia HPV DNA Test Market and Forecast

20. Australia - Cervical Cancer Test Analysis
20.1 Australia - Cervical Cancer Test (Screening) Population
20.1.1 Australia Cervical Cancer Pap Smear Test Population and Forecast
20.1.2 Australia Cervical Cancer HPV DNA Test Population and Forecast

20.2 Australia Cervical Cancer Mortality

20.3 Australia Cervical Cancer Test (Screening) Market
20.3.1 Australia Cervical Cancer Test Market and Forecast
20.3.2 Australia Pap Smear Test Market and Forecast
20.3.3 Australia HPV DNA Test Market and Forecast

21. India - Cervical Cancer Test Analysis
21.1 India - Cervical Cancer Test (Screening) Population
21.1.1 India Cervical Cancer Pap Smear Test Population and Forecast
21.1.2 India Cervical Cancer HPV DNA Test Population and Forecast
21.1.3 India Cervical Cancer VIA Test Population and Forecast

21.2 India Cervical Cancer Test (Screening) Market
21.2.1 India Cervical Cancer Test Market and Forecast
21.2.2 India Pap Smear Test Market and Forecast
21.2.3 India HPV DNA Test Market and Forecast
21.2.4 India VIA Test Market and Forecast

22. China - Cervical Cancer Test Analysis
22.1 China - Cervical Cancer Test (Screening) Population
22.1.1 China Cervical Cancer Pap smear Test Population and Forecast
22.1.2 China Cervical Cancer HPV DNA Test Population and Forecast
22.1.3 China Cervical Cancer VIA Test Population and Forecast

22.2 China - Cervical Cancer Test (Screening) Market
22.2.1 China Cervical Cancer Test Market and Forecast
22.2.2 China Pap Smear Test Market and Forecast
22.2.3 China HPV DNA Test Market and Forecast
22.2.4 China VIA Test Market and Forecast

23. Thailand - Cervical Cancer Test Analysis
23.1 Thailand - Cervical Cancer Test (Screening) Population
23.1.1 Thailand Cervical Cancer Pap Smear Test Population and Forecast
23.1.2 Thailand Cervical Cancer VIA Test Population and Forecast

23.2 Thailand Cervical Cancer Test (Screening) Market
23.2.1 Thailand Cervical Cancer Test Market and Forecast
23.2.2 Thailand Pap smear Test Market and Forecast
23.2.3 Thailand VIA Test Market and Forecast

24. Indonesia - Cervical Cancer Test Analysis
24.1 Indonesia Cervical Cancer Test (Screening) Population
24.1.1 Indonesia Cervical Cancer Pap Smear Test Population and Forecast
24.1.2 Indonesia Cervical Cancer HPV DNA Test Population and Forecast
24.1.3 Indonesia Cervical Cancer VIA Test Population and Forecast
24.1.4 Indonesia Cervical Cancer Both (Pap Smear and VIA) Test Population and Forecast

24.2 Indonesia Cervical Cancer Test (Screening) Market
24.2.1 Indonesia Cervical Cancer Test Market and Forecast
24.2.2 Indonesia Pap smear Test Market and Forecast
24.2.3 Indonesia HPV DNA Test Market and Forecast
24.2.4 Indonesia VIA Test Market and Forecast
24.2.5 Indonesia Cervical Cancer Both (Pap Smear and VIA) Test Market and Forecast

25. Cervical Cancer Test Market Growth Drivers
25.1 Point No. 1
25.2 Point No. 2
25.3 Point No. 3

26. Challenges in Cervical Cancer Test Market
26.1 Point No. 1
26.2 Point No. 2

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Competing in the Global Enteric Disease Testing Market

2016 Competing in the Global Enteric Disease Testing Market

  • $ 11500
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $11,500.  DataPack (test volumes, sales forecasts, supplier shares) $7500. This new 389-page report from VPGMarketResearch.com contains 97 tables and provides analysis of the global enteric ...

Enteric Diseases: Campylobacter, Cryptosporidium, E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, Vibrio, Yersinia

Enteric Diseases: Campylobacter, Cryptosporidium, E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, Vibrio, Yersinia

  • $ 7500
  • Industry report
  • September 2016
  • by Venture Planning Group

Complete report $11,500.  DataPack (test volumes, sales forecasts, supplier shares) $7500. This new 389-page report from VPGMarketResearch.com contains 97 tables and provides analysis of the global enteric ...

World Enteric Diseases Diagnostic Testing Market Future Horizons and Growth Strategies: Supplier Shares by Test, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities

World Enteric Diseases Diagnostic Testing Market Future Horizons and Growth Strategies: Supplier Shares by Test, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities

  • $ 7500
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $11,500.  DataPack (test volumes, sales forecasts, supplier shares) $7500. This new 389-page report from VPGMarketResearch.com contains 97 tables and provides analysis of the global enteric ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.